Revise MBBS

Acute Respiratory Distress Syndrome

Overview

2 forms — neonatal + adult — different clinical setting/etiology/pathogenesis/treatment response/consequences, but SHARED morphologic endpoint: hyaline membrane formation (= hyaline membrane disease, HMD). Adult ARDS synonyms: shock-lung, diffuse alveolar damage, traumatic wet lungs. First recognised WWII shock survivors.

Presentation: Neonatal — dyspnoea within hours of birth, tachypnoea/hypoxia/cyanosis, death within hours if severe. Adult — sudden severe distress, tachypnoea, tachycardia, cyanosis, severe hypoxaemia.

Etiology

Neonatal — hypoxia-driven: preterm, diabetic mothers, C-section, prior premature infants, maternal oversedation, birth asphyxia (cord coils), MALE preponderance (1.5-2x, female lungs mature earlier), many idiopathic.

Adult — Direct: diffuse infection (esp. viral pneumonia), O2 toxicity, toxin/irritant inhalation, gastric aspiration, near-drowning. Indirect: shock (sepsis/trauma/burns), narcotic OD, pancreatitis, drugs (salicylates, colchicine), fat embolism, radiation, multiple transfusions.

Pathophysiology — different mechanisms, same endpoint

Air entry into alveoli needed for hyaline membrane — stillborns never develop it.

Neonatal:

  1. Core defect: surfactant deficiency (type II pneumocytes normally ↑ synthesis pre-birth; prematurity/hypoxia → ↓synthesis)
  2. Surfactant lowers surface tension → deficiency → ↑surface tension → ATELECTASIS
  3. Atelectasis → hypoventilation, hypoperfusion, ischaemic capillary endothelial damage
  4. → ischaemic necrosis of alveolocapillary wall, plasma protein (fibrinogen) exudation → hyaline membrane (fibrin)

Adult: pro-/anti-inflammatory CYTOKINE imbalance (not primary surfactant defect):

  1. Activated macrophages release IL-8/IL-1/TNF; MIF sustains inflammation. ↑Alveolar neutrophils release proteases, PAF, oxidants, leukotrienes (active injury)
  2. Separately: fibrogenic cytokines (TGF-β, PDGF) drive repair — fibroblast proliferation, collagen

Shared downstream: capillary endothelial injury → ↑permeability; type I pneumocyte necrosis → interstitial/intra-alveolar oedema, congestion, fibrin deposition, hyaline membrane. Membrane strips surfactant function → collapse → “STIFF LUNG.” Compensatory type II pneumocyte proliferation attempts surfactant restoration.

Morphology

Gross: normal size but STIFF, congested, heavy, AIRLESS — SINKS IN WATER (classic finding, direct consequence of lost aeration).

Micro: collapsed alternating with dilated alveoli. Alveolar epithelial necrosis + EOSINOPHILIC HYALINE MEMBRANES (fibrin+debris) lining respiratory bronchioles/ducts/proximal alveoli. Interstitial/intra-alveolar oedema, congestion, haemorrhage. ± bronchopneumonia. Later: compensatory pneumocyte proliferation (tufts). Organising stage: interstitial fibrosis obliterating alveoli.

Consequences

  1. Death — neonatal mortality 20-30% (higher <1kg). Adult: stiff lung FAILS TO RESPOND to O2 therapy — severe/fatal.
  2. Resolution — mild neonatal recovers with O2/ventilator support (days). Adult: resolves if trigger controlled — membrane liquefied by neutrophils/macrophages, cleared, aeration restored.
  3. Other sequelae: neonatal survivors → bronchopulmonary dysplasia. Both → desquamative interstitial pneumonia (DIP). Adult survivors → diffuse fibrosing alveolitis (Hamman-Rich syndrome).

Complication of O2/ventilator Rx for neonatal ARDS — O2 toxicity+barotrauma → subacute/chronic fibrosing lung disease, distress persists 3-6 months. Micro: organised hyaline membranes → fibrous alveolar wall thickening, bronchiolitis, peribronchial fibrosis, emphysema, bronchiolar squamous metaplasia.

Clinical relevance

Neonatal (surfactant deficiency) vs adult (cytokine-driven) mechanism divergence → SAME morphologic endpoint = conceptual core — explains why taught together despite different triggers, and why surfactant replacement works specifically in neonatal disease, not adult. “Sinks in water” = direct physical consequence of lost aeration/buoyancy, not arbitrary sign. Adult ARDS failing O2 therapy despite severe hypoxaemia = reflects DIFFUSION/SHUNT problem (thick membrane, collapsed alveoli), not hypoventilation — raising FiO2 alone can’t fix it (unlike pure ventilatory problems). ARDS triggered by direct OR entirely indirect/extrapulmonary insults (sepsis, pancreatitis, burns) = final common pathway of systemic inflammatory injury, not primary lung disease — why it complicates a huge range of critical illness.

Overview

ARDS occurs in two forms — neonatal and adult — with different clinical settings, etiology, pathogenesis, response to treatment, and consequences, but a shared morphologic endpoint: formation of a hyaline membrane in the alveoli, hence the shared alternative name hyaline membrane disease (HMD). Adult ARDS carries several synonyms (shock-lung syndrome, diffuse alveolar damage, acute alveolar injury, traumatic wet lungs, post-traumatic respiratory insufficiency), first recognised in WWII survivors of non-thoracic shock injuries.

Clinical presentation: neonatal ARDS begins with dyspnoea within hours of birth — tachypnoea, hypoxia, cyanosis, and in severe cases death within hours. Adult ARDS presents with sudden, severe respiratory distress, tachypnoea, tachycardia, cyanosis, severe hypoxaemia.

Etiology

Neonatal ARDS — primarily initiated by hypoxia, shortly before or immediately after birth:

  1. Preterm infants.
  2. Infants of diabetic mothers.
  3. Caesarean delivery.
  4. Mothers with previous premature infants.
  5. Excessive maternal sedation depressing infant respiration.
  6. Birth asphyxia (e.g. umbilical cord coils).
  7. Male preponderance (1.5–2×) — female lungs mature earlier.
  8. Many cases remain idiopathic.

Adult ARDS — direct or indirect lung injury:

  • Direct: diffuse pulmonary infection (chiefly viral pneumonia), oxygen toxicity, toxin/irritant inhalation (smoke, war gases, NO₂, metal fumes), gastric aspiration, near-drowning.
  • Indirect: shock (sepsis, trauma, burns), narcotic overdose, pancreatitis, drugs (salicylates, colchicine), fat embolism, radiation, multiple transfusions.

Pathophysiology

Both forms converge on the same final morphologic lesion — alveolocapillary wall damage and hyaline membrane formation — but reach it by genuinely different mechanisms.

Neonatal ARDS

Air entry into alveoli is a prerequisite for hyaline membrane formation — stillborn infants never develop it.

  1. Core defect: deficiency of pulmonary surfactant, normally synthesised by type II alveolar cells and normally increased shortly before birth. Prematurity/neonatal hypoxia reduces surfactant synthesis.
  2. Since surfactant’s main job is lowering alveolar surface tension, its deficiency raises surface tension, causing atelectasis.
  3. Atelectasis → hypoventilation, pulmonary hypoperfusion, ischaemic damage to capillary endothelium.
  4. This produces ischaemic necrosis of the alveolocapillary wall, exudation of plasma proteins (including fibrinogen) into alveoli, and eventual hyaline membrane formation (largely fibrin) on the alveolar surface.

Adult ARDS

Driven by an imbalance between pro-inflammatory and anti-inflammatory cytokines rather than a primary surfactant defect:

  1. Activated pulmonary macrophages release pro-inflammatory cytokines (IL-8, IL-1, TNF); macrophage inhibitory factor (MIF) sustains alveolar inflammation. Increased alveolar neutrophils release proteases, platelet-activating factor, oxidants, and leukotrienes — the agents of active tissue injury.
  2. Separately, fibrogenic cytokines (TGF-β, PDGF) drive the repair phase — fibroblast proliferation and collagen deposition.

Shared downstream pathway (both forms): capillary endothelial injury → increased vascular permeability; type I pneumocyte necrosis. Net effect: interstitial and intra-alveolar oedema, congestion, fibrin deposition, hyaline membrane formation. The hyaline membrane coating strips the alveoli of functional surfactant, causing collapse and a “stiff lung.” Compensatory type II pneumocyte proliferation attempts to restore surfactant secretion.

Morphology

Gross: lungs normal-sized but characteristically stiff, congested, heavy, airless — they sink in water (a classic bedside/autopsy test reflecting the loss of aeration).

Microscopy:

  1. Collapsed alveoli (atelectasis) alternating with dilated alveoli.
  2. Alveolar epithelial necrosis with characteristic eosinophilic hyaline membranes lining respiratory bronchioles, alveolar ducts, and proximal alveoli — composed largely of fibrin admixed with necrotic-cell debris.
  3. Interstitial/intra-alveolar oedema, congestion, intra-alveolar haemorrhage.
  4. Bronchopneumonia may supervene.
  5. With time: compensatory pneumocyte proliferation as tufts of alveolar epithelium.
  6. Organising stage: interstitial fibrosis obliterating alveolar spaces.

Consequences

  1. Death — neonatal mortality 20–30% (higher under 1 kg birth weight); adult ARDS’s stiff lung characteristically fails to respond to oxygen therapy, making it acutely severe and potentially fatal.
  2. Resolution — milder neonatal cases recover with adequate oxygen/ventilator support within days; adult ARDS can resolve if the trigger is controlled — the hyaline membrane is liquefied by neutrophils/macrophages and absorbed, cell debris cleared by macrophages, restoring normal aeration.
  3. Other sequelae:
    • Neonatal survivors may develop bronchopulmonary dysplasia.
    • Both forms may develop desquamative interstitial pneumonia (DIP) from pneumocyte proliferation with superimposed inflammation.
    • Adult ARDS survivors may progress to widespread interstitial fibrosis — diffuse fibrosing alveolitis (Hamman-Rich syndrome).

A complication of oxygen/ventilator treatment for neonatal ARDS — oxygen toxicity and barotrauma produce a subacute/chronic fibrosing lung condition, with respiratory distress persisting 3–6 months. Microscopy: organised hyaline membranes causing fibrous alveolar wall thickening, bronchiolitis, peribronchial fibrosis, emphysema (alveolar dilatation), and bronchiolar squamous metaplasia.

Clinical Relevance

  • The neonatal-versus-adult mechanistic divergence (primary surfactant deficiency versus cytokine-driven inflammatory injury) converging on an identical morphologic endpoint (hyaline membrane) is the conceptual core of this topic — it explains why the two diseases are taught together despite fundamentally different triggers, and why treatment differs (surfactant replacement is specifically useful in neonatal disease, not adult).
  • “Lungs sink in water” is a classic, specific gross/autopsy finding directly explained by the pathophysiology — loss of aeration from surfactant depletion and alveolar collapse removes the buoyancy that normally keeps aerated lung afloat, so the finding is a direct physical consequence of the disease process, not an arbitrary sign.
  • Adult ARDS’s failure to respond to oxygen therapy despite severe hypoxaemia is a critical, testable clinical point — it reflects a diffusion/shunt problem (thickened alveolocapillary membrane, collapsed alveoli) rather than simple hypoventilation, which is why simply raising inspired oxygen concentration cannot fix it the way it would in a purely ventilatory problem.
  • Recognising that ARDS can be triggered by direct lung injury or entirely indirect, extrapulmonary insults (sepsis, pancreatitis, burns) reframes the lung findings as a final common pathway of systemic inflammatory injury, not necessarily a primary pulmonary disease — this is why ARDS is a recognised complication across an enormous range of critical illness, not a disease confined to primary lung pathology.
  • Neonatal ARDS pathogenesis: surfactant deficiency to hyaline membrane, step by step
  • Adult ARDS pathogenesis: cytokine imbalance to hyaline membrane, step by step
  • Both pathways converging on the shared alveolocapillary injury endpoint
📝

My Sticky Notes

Personal revision notes, mnemonics and reminders.

☁Auto-saved
0 / 2000
Revise MBBS
Preview